Overview

Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
A randomised, double-blind, placebo-controlled, two-way crossover physiological study. Designed to evaluate the effects of melanocortin-4 receptor (MC4R) activation on brain activity patterns and behavioural psychometric measures of sexual arousal during visual erotic stimuli in approximately 40 right-handed, heterosexual, premenopausal women aged 18 years and over with Hypoactive Sexual Desire Disorder (HSDD) for at least a 6 month duration.
Phase:
Phase 4
Details
Lead Sponsor:
Imperial College Healthcare NHS Trust
Collaborator:
AMAG Pharmaceuticals, Inc.
Treatments:
alpha-MSH